# NCT03867084 (NCT03867084)

> Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03867084
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hepatocellular Carcinoma
- Interventions: Pembrolizumab; Placebo
- Enrollment: 959
- Primary outcome: Recurrence-Free Survival (RFS)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 18
- YouTube: 11
- Podcasts: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03867084

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03867084", "email": "<work email>"}; the inbox owner confirms by the emailed link.